Using low-level laser therapy to enhance performance in Special Operations Forces
Assessing the Impact of Post-Exercise Photobiomodulation Application on Performance, Recovery, and Behavioral State in Trained Special Operator Population
This study is testing whether low-level laser therapy can help Special Forces personnel improve their performance and recover better during training.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 116 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | Male |
| Sponsor | Musculoskeletal Injury Rehabilitation Research for Operational Readiness Federal |
| Locations | 1 site (Joint Base Lewis McChord, Washington) |
| Trial ID | NCT06380179 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of Photobiomodulation Therapy (PBMT) on the performance and recovery of active-duty Special Forces personnel. Participants will undergo THOR3 training combined with either PBMT or a sham treatment to assess the impact on physical performance and cognitive fatigue. The study aims to provide a noninvasive recovery method that could enhance the training outcomes for military personnel. Previous research has indicated potential benefits of PBMT in athletic performance, but its effects on military tactical athletes remain underexplored.
Who should consider this trial
Good fit: Ideal candidates for this study are active-duty Special Forces personnel who meet specific health criteria and can commit to the intervention.
Not a fit: Patients who are obese, have cardiovascular disease, or are on certain medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve recovery and performance in Special Operations Forces, leading to enhanced operational readiness.
How similar studies have performed: Other studies have shown success with PBMT in athletic populations, suggesting potential for similar benefits in military settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Active-Duty Special Forces Personnel (18-series) * Able to read and understand English language for consent purposes * Able to commit to study intervention and follow-up * Able to participate in THOR3 coach-lead training, without restriction Exclusion Criteria: * Obese (body fat \> 25%) * Cardiovascular disease * Use of select medications (e.g., statins, diuretics, hypertensive agents) * Female * Tattoo in treatment area (body region) * Diagnosis with porphyria (light induced allergy) or photosensitive eczema * Current use of medications associated with sensitivity to heat or light (e.g., amiodarone, chlorpromazine, doxycycline, hydrochlorothiazide, nalidixic acid, naproxen, piroxicam, tetracycline, thioridazine, voriconazole) * Use of pacemaker/underlying cardiac disease * Diagnosed with autoimmune disease(s) * Albinism * Peripheral Neuropathy
Where this trial is running
Joint Base Lewis McChord, Washington
- Joint Base Lewis-McChord — Joint Base Lewis McChord, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Bradley H Cornell, DPT — 1st Special Forces Group Tactical Human Optimization, Rapid Rehabilitation and Reconditioning (THOR3)
- Study coordinator: Bradley H Cornell, DPT
- Email: bradley.h.cornell.mil@army.mil
- Phone: 253-477-2130
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.